Rate My Professor Silke Neumann

Neumann has secured major funding, including the Sir Charles Hercus Fellowship ($599,702, 2023) for "Developing novel targets and drugs for cancer therapy in Aotearoa New Zealand," a Marsden Fund grant ($360,000, 2024) examining molecular mechanisms driving gastric cancer survival, and a Health Research Council Emerging Researcher First Grant ($249,961, 2022) for "Treating gastric cancer according to its biology." Notable publications are "The effects of obesity on anti-cancer immunity and cancer immunotherapy" (Cancers, 2020), "Whole-grain processing and glycemic control in type 2 diabetes: a randomized crossover trial" (Diabetes Care, 2020), and "Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants" (Immunology and Cell Biology, 2014). Her research has garnered over 600 citations. She chairs the OMNI Flow Cytometry user group committee, serves as Academic Leader for Flow Cytometry, and supervises postgraduate students.